USFDA conducts inspection at units of Aurobindo Pharma’s arm

17 Nov 2023 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) at Unit-I & III, Formulation manufacturing facility, of APL Healthcare, a wholly owned subsidiary of Aurobindo Pharma, situated at Telangana, from November 13 to 17, 2023.  The inspection closed with zero observations and a classification of ‘No Action Indicated’ (NAI).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1131.80 28.25 (2.56%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.